globe usa magnifying-glass checkbox g-plus rss youtube fb-round connect-with-us-in connect-with-us-twitter youtube2 facebook linkedin twitter
The website you have requested may contain information on products or uses of such products that are not approved in your country. For specific product and country information please contact Medinol


Ridaforolimus Eluting Coronary Stent System

  • Excellent Clinical Outcomes*
  • Redefining deliverability with a new spring tip
  • Low footprint cobalt-chromium design
  • Optimal conformability and vessel support
  • Elastomeric coating and outstanding surface integrity
  • Eluting Ridaforolimus, a high therapeutic index limus drug


EluNIRTM is distributed in the United States by Cordis Cordis - A Cardinal Health Company


TLF and Stent Thrombosis at 12 Months - BIONICS Study
  • TLF (primary endpoint): Composite of cardiac death, target vssel related MI or ischemia-driven TLR
  • * Kandzari, David E. et al. Randomized comparison of Ridaforolimus- and Zotarolimus-Eluting Coronary Stent in Patients with Coronary Artery Disease (2017) 136: 1304-1314 ** Presented at CRT2018

EluNIR - elastomeric Drug Eluting Stent